Collegium Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Collegium Pharmaceutical wird ein Gewinn- und Umsatzwachstum von 22.3% bzw. 2.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 16.5% pro Jahr wachsen soll.

Wichtige Informationen

18.8%

Wachstumsrate der Gewinne

12.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	2.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:COLL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	742	135	286	367	4
12/31/2025	730	133	328	354	4
12/31/2024	634	106	284	349	3
6/30/2024	577	100	276	277	N/A
3/31/2024	567	93	308	309	N/A
12/31/2023	567	48	274	275	N/A
9/30/2023	547	9	266	268	N/A
6/30/2023	537	-11	235	236	N/A
3/31/2023	525	-29	176	177	N/A
12/31/2022	464	-25	123	124	N/A
9/30/2022	362	-43	93	94	N/A
6/30/2022	314	-35	67	69	N/A
3/31/2022	273	43	56	58	N/A
12/31/2021	277	72	102	104	N/A
9/30/2021	326	104	87	90	N/A
6/30/2021	326	107	102	107	N/A
3/31/2021	321	42	115	121	N/A
12/31/2020	310	27	-280	94	N/A
9/30/2020	308	18	-286	87	N/A
6/30/2020	302	0	-313	59	N/A
3/31/2020	299	-13	-341	30	N/A
12/31/2019	297	-23	21	28	N/A
9/30/2019	296	-11	47	54	N/A
6/30/2019	293	-22	81	90	N/A
3/31/2019	291	-30	123	131	N/A
12/31/2018	280	-39	145	169	N/A
9/30/2018	218	-66	91	114	N/A
6/30/2018	160	-62	39	59	N/A
3/31/2018	90	-70	N/A	-14	N/A
12/31/2017	28	-75	N/A	-67	N/A
9/30/2017	19	-85	N/A	-77	N/A
6/30/2017	7	-98	N/A	-84	N/A
3/31/2017	4	-102	N/A	-87	N/A
12/31/2016	2	-94	N/A	-75	N/A
9/30/2016	0	-76	N/A	-61	N/A
6/30/2016	N/A	-59	N/A	-48	N/A
3/31/2016	N/A	-40	N/A	-31	N/A
12/31/2015	N/A	-20	N/A	-22	N/A
9/30/2015	N/A	-15	N/A	-20	N/A
6/30/2015	N/A	-13	N/A	-18	N/A
3/31/2015	N/A	-12	N/A	-16	N/A
12/31/2014	N/A	-21	N/A	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: COLLDas prognostizierte Gewinnwachstum (15.9% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: COLLDie Erträge des Unternehmens (15.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: COLLDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: COLLDie Einnahmen des Unternehmens (0.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.6% pro Jahr).

Hohe Wachstumseinnahmen: COLLDie Einnahmen des Unternehmens (0.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von COLL in 3 Jahren voraussichtlich hoch sein wird

Collegium Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024

Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024

Price target increased by 8.6% to US$41.00

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

Price target increased by 13% to US$37.75

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Recent updates

Executive VP & Chief Medical Officer recently sold US$351k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Executive VP recently sold US$774k worth of stock

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Collegium Pharmaceutical: Diversifying And Growing

Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) agreed to acquire Ironshore Therapeutics Inc. for approximately CAD 550 million.

Collegium Pharmaceutical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Price target increased by 8.6% to US$41.00

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

New minor risk - Insider selling

Executive VP & Chief Commercial Officer recently sold US$1.1m worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Announces CEO Transition

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?